Perioperative chemotherapy improves survival in esophageal cancer
1. Among patients with resectable esophageal cancer, perioperative chemotherapy with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) resulted in improved survival ...
Tag: chemotherapy
Transarterial chemoembolization with pembrolizumab and levatinib improves survival in unresectable hepatocellular carcinoma
1. Progression-free survival was significantly greater in the lenvatinib plus pembrolizumab group compared to placebo. 2. Overall survival was higher ...
#VisualAbstract: Adjuvant Atezolizumab Does Not Provide Benefit in Early Triple-Negative Breast Cancer
Click here to read this study in JAMA. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
#VisualAbstract: Perioperative Chemotherapy is Superior to Preoperative Chemoradiotherapy in Esophageal Cancer
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
Neoadjuvant Nivolumab/Ipilimumab Vs Chemotherapy in Resectable NSCLC
1. Median event-free survival was 54.8 months with immunotherapy vs 20.9 months with chemotherapy, with HR 0.77 (non-significant). 2. Grade ...
Effect of adjuvant carboplatin intensified chemotherapy versus standard chemotherapy on survival in women with high risk, early stage, triple negative breast cancer (CITRINE): randomised, open label phase 3 trial
1. Adjuvant carboplatin intensified chemotherapy was superior to standard chemotherapy in improving survival outcomes in patients with high-risk, early-stage, triple-negative ...
#VisualAbstract: Cadonilimab Plus Chemotherapy Improves Survival in Recurrent or Metastatic Cervical Cancer
Click here to read this study in The Lancet. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be ...
Addition of pembrolizumab to chemotherapy improves early-stage triple-negative breast cancer survival
1. In this randomized controlled trial, among patients with early-stage triple-negative breast cancer (TNBC), the addition of neoadjuvant and adjuvant ...
Cadonilimab plus chemotherapy improves survival in recurrent or metastatic cervical cancer
1. Cadonilimab plus chemotherapy significantly improved progression-free survival in patients with persistent, recurrent, or metastatic cervical cancer. 2. Common grade ...
Molecular-guided therapy improves survival in unfavorable cancer of unknown primary
1. Patients in the MGT group reported a significantly greater progression-free survival than those in the standard platinum-based chemotherapy group. ...
